RxDoctor Payments Data

Ghassan Khoury, MD

Internal Medicine · Los Angeles, CANPI 1003153214

Payments from drug & device makers

$2,740in general payments, 2019–2025

Across 57 payments — averaging $48.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$2K
  • Gilead$168
  • Dynavax Technologies Corporation$116
  • Pfizer$23
  • AbbVie$19
  • Novo Nordisk$15
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$2,740100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,740 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$182
Medicare patients
13
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
DescovyEmtricitabine/Tenofov Alafenam46$105,583
JardianceEmpagliflozin48$66,402
OzempicSemaglutide35$29,049
TrulicityDulaglutide22$20,001
MounjaroTirzepatide17$16,320
Lantus SolostarInsulin Glargine,hum.Rec.Anlog24$2,774
Atorvastatin Calcium147$1,097
Albuterol Sulfate HfaAlbuterol Sulfate18$645
Tamsulosin Hcl37$562
Levothyroxine Sodium44$523
Metformin Hcl81$483
Rosuvastatin Calcium50$475
Diclofenac Sodium19$453
Chlorthalidone21$434
Losartan Potassium75$411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadDescovy$168$105,58346 claims
Novo NordiskOzempic$15$29,04935 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →